M&A M&A
Lupin sells women's health specialty biz in US to Evofem for $84-M
Source Economic Times (opens in a new tab)BSE Announcement (opens in a new tab)
Mumbai-headquartered publicly listed drugmaker Lupin has sold its US commercial women’s health specialty business to Evofem Biosciences, a biopharmaceutical company focused exclusively on women’s health for about USD 84 million (including future contingent milestones).Lupin’s US Commercial Women’s Health Specialty Business is primarily focused on commercialising Solosec (secnidazole) 2g oral granules. This single-dose antimicrobial agent is used to treat bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.